(Q37325828)

19 August 2017

4 references

25 April 2019

2 October 2019

7 November 2019

30 January 2021

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review (English)

1 reference

cholinesterase inhibitors

19 August 2017

3 references

25 April 2019

2 October 2019

7 November 2019

1 reference

2 October 2019

1 reference

7 November 2019

1 reference

ChEBI release 2020-05-28

ChEBI ID

8874

1 reference

30 January 2021

1 reference

A Kurz

1

1 reference

19 August 2017

M Farlow

series ordinal

2

1 reference

19 August 2017

G Lefèvre

series ordinal

3

1 reference

19 August 2017

language of work or name

1 reference

1 May 2009

5 references

International Journal of Clinical Practice

19 August 2017

25 April 2019

2 October 2019

7 November 2019

30 January 2021

5 references

19 August 2017

25 April 2019

2 October 2019

7 November 2019

30 January 2021

63

1 reference

19 August 2017

5

1 reference

19 August 2017

799-805

1 reference

Creative Commons Attribution 2.5 Generic

19 August 2017

4 references

25 April 2019

2 October 2019

7 November 2019

on focus list of Wikimedia project

30 January 2021

ScienceSource

0 references

cites work

Pharmacokinetic rationale for the rivastigmine patch

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Transdermal delivery of drugs for urologic applications: basic principles and applications

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

The 500 Dalton rule for the skin penetration of chemical compounds and drugs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Confidence interval criteria for assessment of dose proportionality.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Rivastigmine exposure provided by a transdermal patch versus capsules.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Rivastigmine. A review of its use in Alzheimer's disease.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2734925

Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease

3 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19392927

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19392927

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1742-1241.2009.02052.X

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19392927

1 reference